| Company Name: |
Innate Immunotherapeutics Limited (ACN 165 160 841) |
|
Business Description: |
Innate Immunotherapeutics Limited is a medical biotechnology company with offices in Sydney (Australia) and Auckland (New Zealand). The Company has designed and manufactured a unique immunomodulator microparticle technology. This technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as Multiple Sclerosis. The same technology can be used in the design of better vaccines to potentially treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis.
|
|
| Shares on Issue: |
222,848,213 |
| Options on Issue: |
24,160,000 (at varying exercise prices and expiry dates) |
|
| Market Listings: |
Australian Securities Exchange (ASX:IIL) |
|
| Directors: |
Michael Quinn, Independent Chairman
Liz Hopkins, Independent Director
Andrew Sneddon, Independent Director
Chris Collins, Director
Dr Robert Peach, Independent Director
Simon Wilkinson, Managing Director |
|
| Management: |
Simon Wilkinson, CEO
Dr Gill Webster, CSO
Janette Dixon, VP Corporate Development
|
|
Registered Office:
Administration Office: |
Suite 401, 35 Lime Street
Sydney 2000
Australia
4B Walls Road, Penrose, Auckland
PO Box 91 806, Victoria Street West
Auckland 1142
New Zealand
Telephone: + 64 9 525 0532
Facsimile: + 64 9 525 0537
|
|
Auditors: |
Grant Thornton Audit Pty
GPO Box 4736
Melbourne 3001
Australia
|
|
Download: |
Click here to Download the latest Fact Sheet
|
